查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138266

全球額顳葉疾病藥物市場 - 2022-2029

Global Frontotemporal Disorders Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

全球額顳葉疾病治療市場的增長受到癡呆症和其他額顳葉疾病患病率上升、藥物開發補貼增加以及政府和非政府組織資助等因素的推動，是推動增長的主要因素.

預計在預測期內，不斷進步的技術進步將推動全球額顳葉疾病治療市場。

根據世界衛生組織 (WHO) 的數據，大約有 5000 萬人患有癡呆症，每年大約有 1000 萬新病例，這有望推動該行業的發展。

額顳葉癡呆佔所有癡呆患者的 2-5%。預計到 2050 年，癡呆症的患病率將增加兩倍。根據癡呆症統計研究所的數據，預計癡呆症患者人數將從 2018 年的 5000 萬增加到 2050 年的 1.52 億，增加 204%。預計癡呆患者人數的增加將進一步增加額顳葉癡呆病例，進一步增加對額顳葉疾病治療藥物和藥物的需求。

政府增加對尋找目標疾病治療方法的研究工作的支持和資金也有望推動市場增長。一些組織參與了新藥的開發，包括美國國立衛生研究院 (NIH)、阿爾茨海默氏症協會和美國國家老齡化研究所。 2019 年，美國國立衛生研究院在阿爾茨海默病相關癡呆 (ADRD) 研究項目上花費了約 3.87 億美元。預計這些舉措將在預測期內推動市場增長。

新興國家對目標疾病缺乏認識可能會阻礙市場增長

額顳葉癡呆作為癡呆症的治療劑在世界範圍內被廣泛認可。糟糕的治療方案和缺乏新療法也限制了額顳葉疾病治療市場的增長。

行業分析

全球額顳葉疾病治療市場根據各種行業因素、未滿足的需求（如波特五力分析、供應鏈分析、監管分析和定價分析）對市場進行了深入分析。 .

細分分析

抗抑鬱藥部分預計在預測期內（2022-2029 年）以最快的複合年增長率增長

根據藥物類別，全球額顳葉疾病治療市場細分為抗精神病藥、認知改善劑、CNS 興奮劑、抗抑鬱藥等。其中，抗抑鬱藥預計將在預測期內提供有利可圖的機會。抗抑鬱藥主要用於治療抑鬱症和其他疾病，例如心境惡劣、強迫症 (OCD)、焦慮症、神經性疼痛、進食障礙和慢性疼痛。醫生通常會開出其他幾種抗抑鬱藥來有效管理患者的健康。此外，選擇性5-羥色胺再攝取抑製劑（SSRIs）已被證明有益於治療額顳葉疾病。

2018 年 10 月，靈北在印度推出 Brintellix 片劑，用於治療重度抑鬱症。此外，2019年4月，魯邦在美國市場推出抗抑鬱藥氟西汀片。該片劑可用於治療重度抑鬱症和強迫症。因此，由於患者數量的增加和最近的產品發布，預計市場在預測期內將在全球範圍內實現高速增長。

本報告提供了大約 40 多個市場數據表、45 多個圖表和 180 頁有關全球額顳葉治療市場的信息。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按治療類別劃分的市場細分
  • 按指標劃分的市場細分
  • 按分銷渠道劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 額顳葉疾病的患病率不斷上升
      • 政府和非政府組織的資助增加
    • 限制
      • 治療費用高
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 流行病學
  • 管道分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 未滿足的需求
  • COVID-19 影響分析

第 6 章按藥物類別

    • 認知功能改善劑
    • 抗精神病藥
      • 阿立□唑
      • 帕潘立酮
      • 奧氮平
      • 利培酮
      • 奎硫平
      • 齊拉西酮
    • 抗抑鬱藥
      • 安非他酮
      • 氟伏沙明
      • 西□普蘭
      • 氟西汀
      • 米曲西平
      • 帕羅西汀
      • 捨曲林
    • 中樞神經系統興奮劑
    • 其他

第 7 章按功效和作用

    • 行為改良額顳葉癡呆 (BFTD) (BFTD)
    • 原發性進行性失語症 (PPA)
      • 語義 PPA
      • 語法 PPA
      • 徽標繪畫 PPA
    • 運動功能下降
      • 皮質基底綜合徵 (CBS)
      • 進行性核上性麻痺 (PSP)

第 8 章分銷渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店
  • 其他

第 9 章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 10 章競爭格局

  • 競爭場景
  • 市場定位/市場份額分析
  • 併購分析

第 11 章公司簡介

  • Apotex Inc.
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Johnson & Johnson
  • Auro Pharma
  • Pfizer Inc.
  • Teva Pharmaceuticals USA, Inc.
  • AstraZeneca plc.
  • Mylan N.V.
  • Sanofi S.A.
  • Valeant Pharmaceutical International
  • Eli Lilly and Company（LIST NOT EXHAUSTIVE）

第12章 DataM

簡介目錄
Product Code: DMMD2666

Market Overview

The Frontotemporal Disorders Treatment Market size was valued at USD 721.4 million in 2021 and is estimated to reach at a compound annual growth rate (CAGR) of 6.50% over the forecast period 2022 to 2029.

Frontotemporal disorder, commonly known as Pick disease, is a form of dementia that is caused by a family of brain disorders known as frontotemporal lobar degeneration (FTLD). Frontotemporal dementia is a rare type of dementia that causes behavior and language problems. Dementia is associated with disorders of mental abilities caused by some changes and damage in the brain and affects the front and sides of the brain.

The Frontotemporal Disorders Treatment Market study analysis offers an in-depth outlook on the market containing both quantitative, and qualitative data. It gives an outlook and forecast of the global market based on the Frontotemporal Disorders Treatment Market segmentation by drug class, procedure, and Distribution Channel. It also provides market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global Frontotemporal Disorders Treatment Market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Market Dynamics

The global frontotemporal disorders treatment market growth is driven by certain factors such as the rising prevalence of dementia and other frontotemporal disorders, increasing drug development grants, and funding by the government as well as non-government organizations are the key factors driving the market growth.

The rising technological advancements, is expected to drive the global frontotemporal disorders treatment market during the forecast period;

As per the World Health Organization, about 50 Mn people have dementia, and there are around 10 Mn new cases annually, which is anticipated to boost the industry growth.

Frontotemporal dementia accounts for 2-5% of the overall dementia cases. The prevalence of dementia is projected to be triple by 2050. As per the Dementia Statistics Organization, the number of people living with dementia is projected to increase by 204% from 50 million in 2018 to 152 million by 2050. The increasing number of dementia cases will further increase the cases of frontotemporal dementia, which is expected to drive more demand for frontotemporal disorders treatment drugs and medications.

Also, the rising government support and funding for research activities to find the treatment of target disease is expected to drive the growth of the market. Several organizations are involved in developing new medications, including the National Institute of Health (NIH), Alzheimer's Association, and National Institute on Aging. In 2019, the NIH spent around US$ 387 million on research projects for Alzheimer's Disease-Related Dementias (ADRD). These initiatives are expected to boost market growth over the forecast period.

Lack of awareness towards the target disease in a developing country are likely to hinder the market growth

However, lack of proper diagnosis and higher chances of misunderstanding with Alzheimer's disease is restraining the growth of the frontotemporal dementia treatment market. Additionally poor treatment regimens lack of novel therapies is also limiting the Frontotemporal dementia treatment market growth.

Industry Analysis

The global frontotemporal disorders treatment market provides in-depth analysis of the market based on various industry factors such as porter's five force analysis, supply chain analysis, regulatory analysis, pricing analysis etc, unmet needs.

Segmentation Analysis

The antidepressants segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Based on drug class, the global frontotemporal disorders treatment market is segmented into antipsychotics, cognitive enhancers, CNS stimulants, antidepressants, and others. Among these, antidepressants are expected to show a lucrative opportunity over the forecast period. Antidepressant drugs are mainly used for the treatment of depressive disorders and other conditions, such as dysthymia, obsessive-compulsive disorder (OCD), anxiety disorders, neuropathic pain, eating disorders, and chronic pain, among others. Several other types of antidepressants are widely prescribed by physicians to manage patient health effectively. Also, (SSRIs) selective serotonin reuptake inhibitors prove beneficial for the treatment of frontotemporal disorders.

In October 2018, Lundbeck launched Brintellix tablets, which are used for the treatment of Major Depressive Disorder in India. Furthermore, in April 2019, Lupin launched antidepressant Fluoxetine tablets in the American market. The tablets are indicated for the treatment of the major depressive disorder, and obsessive-compulsive disorder. Thus, owing to the rising patient pool and recent product launches, the market is expected to witness high growth across the globe over the forecast period.

Geographical Analysis

North America region holds the largest market share of the global frontotemporal disorders treatment market

North America region is dominating the global frontotemporal disorders treatment market accounting for the largest market share in 2019, owing to a large presence of advanced healthcare facilities and infrastructure in developed countries, such as the United States. Also, the rising prevalence of frontotemporal disorders in this region is driving the growth of the market. For instance, according to the National Institute of Neurological Disorders and Stroke, Alzheimer's disease alone, as one dementia disorder, affects over 5 million people in the United States. The toll on individuals, society, and caregivers is enormous and is expected to increase as the population ages. Frontotemporal dementia falls under rare diseases or orphan indications.

In the United States, around 30,000 to 40,000 patients are suffering from frontotemporal disorders. Treatment of frontotemporal disorders falls under the Orphan Drug Act of 1983 as orphan drug indications are those which affect less than 200,000 people in the U.S. along with similar legislation in Europe. Orphan drug designation to FTD allows the continuation of clinical trials and development of a drug with commercial incentives, prioritizing consultation by FDA on clinical studies and reduction in regulatory fees.

Competitive Landscape

The global frontotemporal disorders treatment market is competitive and consists of several major players in the market. Some of the key players which are contributing to the growth of the market include Johnson & Johnson, Apotex Inc., Auro Pharma, Pfizer Inc., Teva Pharmaceuticals USA, Inc., AstraZeneca plc., Mylan N.V., Sanofi S.A., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the frontotemporal disorders treatment market globally. For instance, on June 15th, 2020, ACADIA Pharmaceuticals Inc. submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to support a potential new indication for NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). The FDA previously granted Breakthrough Therapy Designation for pimavanserin for the treatment of hallucinations and delusions associated with DRP.

Key Companies to Watch

Pfizer Inc

Overview: Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

Product Portfolio: ZFP-TFs to down-regulate the expression of tau, a protein associated with Alzheimer's disease and frontotemporal dementia (FTD).

The global frontotemporal disorders treatment market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Drug Class
  • 3.2. Market snippet by Indication
  • 3.3. Market snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Frontotemporal Disorders
      • 4.1.1.2. Increasing Funding by Government & Non-Government Organizations
      • 4.1.1.3. XX
    • 4.1.2. Restraints:
      • 4.1.2.1. High Cost of treatment
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Unmet Needs
  • 5.8. COVID-19 Impact Analysis

6. By Drug Class

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
  • 6.3. Market Attractiveness Index, By Drug Class Segment
    • 6.3.1. Cognitive Enhancers*
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 6.3.2. Antipsychotics
      • 6.3.2.1. Aripiprazole
      • 6.3.2.2. Paliperidone
      • 6.3.2.3. Olanzepine
      • 6.3.2.4. Risperidone
      • 6.3.2.5. Quetiapine
      • 6.3.2.6. Ziprasidone
    • 6.3.3. Antidepressants
      • 6.3.3.1. Bupropion
      • 6.3.3.2. Fluvoxamine
      • 6.3.3.3. Citalopram
      • 6.3.3.4. Fluoxetine
      • 6.3.3.5. Mitrazepine
      • 6.3.3.6. Paroxetine
      • 6.3.3.7. Sertraline
    • 6.3.4. CNS stimulants
    • 6.3.5. Others

7. By Indication

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 7.3. Market Attractiveness Index, By Indication Segment
    • 7.3.1. Behaviour Variants Frontotemporal Dementia. (BFTD)*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Primary Progressive Aphasia (PPA)
      • 7.3.2.1. Semantic PPA
      • 7.3.2.2. Agrammatic PPA
      • 7.3.2.3. Logopenic PPA
    • 7.3.3. Motor Decline
      • 7.3.3.1. Corticobasal syndrome (CBS)
      • 7.3.3.2. Progressive supranuclear palsy (PSP)

8. By Distribution Channel

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 8.3. Market Attractiveness Index, By Distribution Channel Segment
    • 8.3.1. Hospital Pharmacies*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
    • 8.3.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. The U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. The Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Apotex Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Johnson & Johnson
  • 11.3. Auro Pharma
  • 11.4. Pfizer Inc.
  • 11.5. Teva Pharmaceuticals USA, Inc.
  • 11.6. AstraZeneca plc.
  • 11.7. Mylan N.V.
  • 11.8. Sanofi S.A.
  • 11.9. Valeant Pharmaceutical International
  • 11.10. Eli Lilly and Company (LIST NOT EXHAUSTIVE)

12. DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us